Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET. Company Participants. Camilla Zuckero - VP, IR and Corporate Affairs Derek Ma ...

Pacific Biosciences' Q4'24 results missed estimates. Growth in genetic data usage noted, but research funding uncertainties ...

We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at ...

With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...

Innovation Works' AlphaLab accelerator named its first ever unified cohort. Selected companies will receive up to $100,000 in ...

Enveric Biosciences secures a U.S. patent for non-hallucinogenic mescaline derivatives targeting addiction, ADHD and anxiety.

Anixa Biosciences, Inc. ("Anixa" or the "Company") , a biotechnology company focused on the treatment and prevention of cancer, today announced has it has dosed its final patient in the third cohort ...

Pomerantz LLP announces that a class action lawsuit has been filed against Alarum Technologies Ltd. ("Alarum" or the "Company") and certain officers. The class action, filed in the United States ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

Globalstar, Inc. GSAT is scheduled to report fourth-quarter 2024 results on Feb. 27, after the closing bell. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. The Zacks ...

Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 –– Biomarker ...